Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Venetoclax clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Venetoclax as a study intervention. Browse Venetoclax recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 3:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
465
Shown on this page
12
Current sort
Recently updated
Therapy scope
Venetoclax
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Venetoclax. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 121–132 of 465 matching trials for Venetoclax.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Recruiting Phase 1Phase 2 Interventional

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

NCT04588922
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
SLS009, venetoclax, azacitidine
Drug
Lead sponsor
Sellas Life Sciences Group
Industry
Eligibility
12 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 26, 2026, 3:19 AM EDT
Recruiting Phase 3 Interventional

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

NCT06652438
View directory record Official record
Conditions
Acute Myeloid Leukemia, Adult
Interventions
Revumenib, Placebo
Drug
Lead sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Other
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 26, 2026, 3:19 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT05057494
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Interventions
Acalabrutinib, Venetoclax, Obinutuzumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
19
States / cities
Tucson, Arizona • La Jolla, California • Longmont, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 26, 2026, 3:19 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma

NCT05951959
View directory record Official record
Conditions
Mantle Cell Lymphoma (MCL)
Interventions
Acalabrutinib, Venetoclax, Rituximab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
Hackensack, New Jersey • Stony Brook, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 26, 2026, 3:19 AM EDT
Recruiting Phase 2 Interventional

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

NCT07471841
View directory record Official record
Conditions
IDH1 Mutation, Relapsed / Refractory AML
Interventions
Olutasidenib, Azacitidine (AZA)
Drug
Lead sponsor
Timothy Pardee
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 26, 2026, 3:19 AM EDT
Recruiting Phase 2 Interventional

Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

NCT07734038
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Venetoclax, Zanubrutinib
Procedure · Drug
Lead sponsor
Kerry Rogers
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 26, 2026, 3:19 AM EDT
Recruiting Phase 1 Interventional

High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

NCT07177079
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Venetoclax, High-dose ascorbate, Decitabine
Drug
Lead sponsor
Kittika Poonsombudlert
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 26, 2026, 3:19 AM EDT
Recruiting Phase 1 Interventional

CIML NK Cells With Venetoclax for AML

NCT06152809
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia, Leukemia, Myeloid
Interventions
Cytokine-Induced Memory-like Natural Killer Cells, Interleukin-2, Venetoclax
Biological · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 26, 2026, 3:19 AM EDT
Recruiting Phase 1 Interventional

Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia

NCT07439211
View directory record Official record
Conditions
Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia, Refractory Leukemia
Interventions
Eganelisib, Azacitidine, Venetoclax
Drug
Lead sponsor
Jacqueline Garcia, MD
Other
Eligibility
18 Years to 90 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 26, 2026, 3:19 AM EDT
Active, not recruiting Phase 2 Interventional

Cladribine Venetoclax in Monocytic AML

NCT06232655
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Cladribine, Venetoclax, Azacitidine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 26, 2026, 3:19 AM EDT
Suspended Phase 1 Interventional

Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

NCT06514261
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Buccal Swab, Iadademstat, Venetoclax
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Irvine, California • Orange, California • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 26, 2026, 3:19 AM EDT
Recruiting Early Phase 1 Interventional

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

NCT07059975
View directory record Official record
Conditions
Acute Myeloid Leukemia, Pediatric AML
Interventions
Idarubicin Hydrochloride, Fludarabine, Cytarabine (Ara-C), Venetoclax, Etoposide, Asparaginase Erwinia Chrysanthemi (recombinant), Intrathecal triple, SOC
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Month to 30 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 26, 2026, 3:19 AM EDT

About this Venetoclax clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Venetoclax as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Venetoclax.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Venetoclax.